Cargando…
The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma
BACKGROUND: Cervical adenosquamous carcinoma (ASC) was previously thought to be a subtype of cervical adenocarcinoma, but recent studies have found that the clinical features of the two diseases are different. Moreover, the pathological characteristics, survival, prognosis, and optimal ASC therapy r...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003999/ https://www.ncbi.nlm.nih.gov/pubmed/35410240 http://dx.doi.org/10.1186/s12905-021-01588-8 |
_version_ | 1784686198165340160 |
---|---|
author | Liu, Yawen Tu, Haiyan Zhang, Lingling Zhong, Meiling Wang, Yanan Li, Ling Xiang, Xiaojun |
author_facet | Liu, Yawen Tu, Haiyan Zhang, Lingling Zhong, Meiling Wang, Yanan Li, Ling Xiang, Xiaojun |
author_sort | Liu, Yawen |
collection | PubMed |
description | BACKGROUND: Cervical adenosquamous carcinoma (ASC) was previously thought to be a subtype of cervical adenocarcinoma, but recent studies have found that the clinical features of the two diseases are different. Moreover, the pathological characteristics, survival, prognosis, and optimal ASC therapy remain unknown. This study aims to retrospectively analyze the postoperative survival of patients with early-stage ASC and to evaluate their condition after treatment with postoperative concurrent chemoradiotherapy (CCRT) and prophylactic irradiation of the para-aortic lymphatic drainage area. METHODS: This study enrolled 131 patients with pathologically confirmed ASC screened from 3502 patients with confirmed stage I–II cervical cancer diagnosis who had completed surgical treatments in our hospital. Among the 131 enrolled patients, 75 patients received CCRT, 33 patients received chemotherapy (CT), and 23 patients did not receive adjuvant treatment (named surgery alone (S alone). Of the 75 patients CCRT, 43 patients received prophylactic irradiation of the para-aortic lymphatic drainage area. The efficacy of the postoperative treatments of patients among groups (CCRT, CT, and S alone) was compared. RESULTS: The median follow-up time, age, and overall survival (OS) were 76 months, 43 years, and 74 months, respectively. The 3- and 5-year survival rates were 82% and 71.4%, respectively. The median disease-free survival (DFS) was 64 months. Cox regression analysis showed that postoperative adjuvant treatment modalities and positive lymph node metastases were associated with OS and DFS. Patients who received CCRT treatment had higher OS and DFS than those with CT and S alone. Prophylactic irradiation of the para-aortic lymphatic drainage area did not improve the OS and DFS of patients with CCRT treatment. However, further subgroup analysis suggested that it might improve survival rates in patients who had positive pelvic lymph nodes as confirmed by postoperative pathology. CONCLUSION: Postoperative CCRT improved the survival rates in patients with early-stage ASC. The value of prophylactic irradiation of the para-aortic lymphatic drainage area remains debatable, but it may benefit patients with pelvic lymph node involvement. |
format | Online Article Text |
id | pubmed-9003999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90039992022-04-13 The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma Liu, Yawen Tu, Haiyan Zhang, Lingling Zhong, Meiling Wang, Yanan Li, Ling Xiang, Xiaojun BMC Womens Health Research Article BACKGROUND: Cervical adenosquamous carcinoma (ASC) was previously thought to be a subtype of cervical adenocarcinoma, but recent studies have found that the clinical features of the two diseases are different. Moreover, the pathological characteristics, survival, prognosis, and optimal ASC therapy remain unknown. This study aims to retrospectively analyze the postoperative survival of patients with early-stage ASC and to evaluate their condition after treatment with postoperative concurrent chemoradiotherapy (CCRT) and prophylactic irradiation of the para-aortic lymphatic drainage area. METHODS: This study enrolled 131 patients with pathologically confirmed ASC screened from 3502 patients with confirmed stage I–II cervical cancer diagnosis who had completed surgical treatments in our hospital. Among the 131 enrolled patients, 75 patients received CCRT, 33 patients received chemotherapy (CT), and 23 patients did not receive adjuvant treatment (named surgery alone (S alone). Of the 75 patients CCRT, 43 patients received prophylactic irradiation of the para-aortic lymphatic drainage area. The efficacy of the postoperative treatments of patients among groups (CCRT, CT, and S alone) was compared. RESULTS: The median follow-up time, age, and overall survival (OS) were 76 months, 43 years, and 74 months, respectively. The 3- and 5-year survival rates were 82% and 71.4%, respectively. The median disease-free survival (DFS) was 64 months. Cox regression analysis showed that postoperative adjuvant treatment modalities and positive lymph node metastases were associated with OS and DFS. Patients who received CCRT treatment had higher OS and DFS than those with CT and S alone. Prophylactic irradiation of the para-aortic lymphatic drainage area did not improve the OS and DFS of patients with CCRT treatment. However, further subgroup analysis suggested that it might improve survival rates in patients who had positive pelvic lymph nodes as confirmed by postoperative pathology. CONCLUSION: Postoperative CCRT improved the survival rates in patients with early-stage ASC. The value of prophylactic irradiation of the para-aortic lymphatic drainage area remains debatable, but it may benefit patients with pelvic lymph node involvement. BioMed Central 2022-04-12 /pmc/articles/PMC9003999/ /pubmed/35410240 http://dx.doi.org/10.1186/s12905-021-01588-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Liu, Yawen Tu, Haiyan Zhang, Lingling Zhong, Meiling Wang, Yanan Li, Ling Xiang, Xiaojun The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma |
title | The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma |
title_full | The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma |
title_fullStr | The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma |
title_full_unstemmed | The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma |
title_short | The best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma |
title_sort | best postoperative adjuvant therapy for patients with early stage cervical adenosquamous carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003999/ https://www.ncbi.nlm.nih.gov/pubmed/35410240 http://dx.doi.org/10.1186/s12905-021-01588-8 |
work_keys_str_mv | AT liuyawen thebestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT tuhaiyan thebestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT zhanglingling thebestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT zhongmeiling thebestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT wangyanan thebestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT liling thebestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT xiangxiaojun thebestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT liuyawen bestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT tuhaiyan bestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT zhanglingling bestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT zhongmeiling bestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT wangyanan bestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT liling bestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma AT xiangxiaojun bestpostoperativeadjuvanttherapyforpatientswithearlystagecervicaladenosquamouscarcinoma |